Janssen ’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations

TITUSVILLE, NJ, November 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first impact summary for its Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now multi-year initiative, designed to create urgency and action around the hidden threat of peripheral artery disease (PAD)-related amputation. In its inaugural year, Save Legs. Change Lives.™ focused on reaching Black Americans, who are up to four times more likely than white Americans to have a PAD-related amputation.1 With this critical initiative, Janssen is focused on helping those at risk of PAD through more than 12 programs across three focus areas: empowering individuals and communities placed at an increased risk of PAD, collaborating with powerful partners, and driving research.“We are already seeing the power of Save Legs. Change Lives.™ to systemically break down barriers and usher in a new era of healthcare – one that is more diverse, harnesses equity and ensures inclusive PAD care for all,” said Richard Browne, MD, FACC, Senior Medical Executive, Health Systems Strategy and Leader of the Cardiovascular Health Equity Advisory Council, Janssen Scientific Affairs, LLC. “We’ve shared PAD information with millions of people, implemented thousands of free screenings, and are advancing research that gets to the heart of inequities that drive increased risk of PAD-related amputations within the Black community. And we are just getting started.”Empowe...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news